All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Murepavadin
Therapeutic Area: Infections and Infectious Diseases Product Name: POL7080
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
The phase I study will evaluate the safety and tolerability of single and multiple ascending doses of inhaled murepavadin in healthy volunteers and will be jointly funded by Polyphor and the European Innovative Medicines Initiative (IMI).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ensovibep
Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
MP0420 is designed to bind the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein at three distinct locations to prevent viral entry into cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rifabutin
Therapeutic Area: Infections and Infectious Diseases Product Name: BV100
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2020
Details:
BioVersys has developed a proprietary human IV formulation of BV100 for the CRAB hospital market and elucidated the unique mode of action that accounts for its tremendous potency and coverage of clinical CRAB isolates.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AZD7442
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD7442
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 30, 2020
Details:
Lonza will manufacture drug substance (DS) for AZD7442 at Lonza's facilities in Portsmouth (US). Operations are expected to start in H1 2021. AstraZeneca will be one of the first companies to access Lonza's new mid-scale facilities in Portsmouth, NH (USA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): V-306
Therapeutic Area: Infections and Infectious Diseases Product Name: V-306
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
All 20 subjects received the first dose of V-306 or placebo, as planned and early clinical experience is encouraging with no adverse events reported to date.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RG6217
Therapeutic Area: Infections and Infectious Diseases Product Name: RG6217
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2020
Details:
Roche has canned a phase 1 test of a potential hepatitis B antiviral as part of its third-quarter clean-up of unwanted pipeline drugs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): V-306
Therapeutic Area: Infections and Infectious Diseases Product Name: V-306
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 16, 2020
Details:
The financing will ensure the company can complete the phase 1 clinical trial of its lead asset V-306 in RSV, advance pre-clinical development of its vaccine candidates against SARS-CoV-2, progress other research collaborations and strengthen the team.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA-1273
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 01, 2020
Details:
Moderna plans to establish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at both sites.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LXE408
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 25, 2020
Details:
Within the scope of the agreement, Novartis is responsible for completing Phase I clinical trials and DNDi will lead Phase II and Phase III development in India.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
